Navigation Links
Amgen Positioned to Deliver Attractive Growth Over Next Five Years
Date:11/7/2008

medicines, Amgen remains committed to advancing science to dramatically improve people's lives. To learn more about our pioneering science and our vital medicines, visit http://www.amgen.com.

Forward-Looking Statements

This news release contains forward-looking statements that are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including estimates of revenues, operating margins, capital expenditures, cash, other financial metrics, expected legal, arbitration, political, regulatory or clinical results or practices, customer and prescriber patterns or practices, reimbursement activities and outcomes and other such estimates and results. Forward-looking statements involve significant risks and uncertainties, including those discussed below and more fully described in the Securities and Exchange Commission (SEC) reports filed by Amgen, including Amgen's most recent annual report on Form 10-K and most recent periodic reports on Form 10-Q and Form 8-K. Please refer to Amgen's most recent Forms 10-K, 10-Q and 8-K for additional information on the uncertainties and risk factors related to our business. Unless otherwise noted, Amgen is providing this information as of Nov. 7, 2008, and expressly disclaims any duty to update information contained in this news release.

No forward-looking statement can be guaranteed and actual results may differ materially from those we project. Discovery or identification of new product candidates or development of new indications for existing products cannot be guaranteed and movement from concept to product is uncertain; consequently, there can be no guarantee that any particular product candidate or devel
'/>"/>

SOURCE Amgen
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Amgen and Genentech Brace Themselves for Heavy Pressure From Biogenerics Manufacturers
2. More Than 230 Cyclists to Ride in Amgen California Coast Classic Bike Tour to Raise $1.3 Million for Arthritis Foundation
3. Entry of Biogenerics and Decreasing Use of Amgens Epogen and Johnson & Johnsons Procrit Will Cause a $2.8 Billion Decline in the Drug Market for Chemotherapy-Induced Anemia by 2016
4. Oxford Genome Sciences and Amgen to Jointly Discover Novel Therapeutic Antibodies in Cancer
5. Pfizer, Genentech, Amgen, Bayer, Wyeth, Abbott, Merck and Additional Leading Pharmaceutical Companies Participating During ExL Pharmas Fall Line Up!
6. Co-Inventor of Amgens Aranesp(R) Technology Directs Worldwide Patent Strategy for Diffusion Pharmaceuticals First-in-Class Oxygen Enhancing Therapeutics
7. Amgen Announces Webcast of 2008 Third Quarter Financial Results
8. Amgens Third Quarter 2008 Adjusted Earnings Per Share Increased 14 Percent to $1.23
9. Call for Applications: The Amgen Award for Science Teaching Excellence
10. Amgen to Webcast 2008 Business Review Meeting on November 7 From Millennium Hotel in New York
11. New Therapy by Merck is Positioned to Earn Gold-Standard Status by 2011 in the Treatment of Chemotherapy-Induced Nausea and Vomiting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... and NEW YORK , ... PTBI, PTBIW), a biopharmaceutical company advancing patient care in ... offering of 3,500,000 shares of common stock, and warrants ... common stock, at an offering price of $4.00 per ... per share exercise price of $5.00, are exercisable immediately, ...
(Date:12/24/2014)... 23, 2014 GMO corn cases filed ... Syngenta, are in the process of being consolidated in ... case is In Re: Syngenta AG MIR 162 Corn ... for the District of Kansas. , Management of the ... over to U.S. District Judge John W. Lungstrum.* , ...
(Date:12/24/2014)... According to Ross Selinger, President of Selinger ... the national office market continues to be strong, driven by ... by the third quarter’s surprising 3.9% GDP, unemployment decreasing to ... have held inflation down and the Fed is keeping interest ... remaining soft. , This solid economic news is having a ...
(Date:12/24/2014)... Pipette.com announces their Holiday in ... submit their #HolidayInTheLab pictures for a chance to win ... For those struggling to think of a holiday gift ... the Lab Contest provides the ideal holiday presents. The ... send pictures of their chemistree, holiday sweaters, as well ...
Breaking Biology Technology:PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 2PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 3Carey Danis & Lowe Reports on Syngenta GMO Corn Transfer Order 2ITRA Global Reports Long Island Is Out of Sync With The National Office Market 2ITRA Global Reports Long Island Is Out of Sync With The National Office Market 3Major Pipette Distributor Pipette.com Announces their Holiday in the Lab Contest 2
... that holds much promise for the future of solar ... energy to produce clean and renewable liquid transportation fuels, ... National Laboratory (Berkeley Lab) have reported a technique by ... semiconductor cadmium-selenide was increased 100,000 times. "The key ...
... N.Y., Sept. 11 BioSpecifics Technologies Corp. (Nasdaq: ... products, today announced that BioSpecifics, President, Tom Wegman, will present ... on Wednesday, September 16, 2009, at 9:00 am ET at ... NY. , , A live webcast of ...
... LEUVEN, Belgium, September 11 , ... Year are,Recognised in Nominations , ThromboGenics ... and development of innovative treatments for eye,disease, vascular disease and ... "Biotech Company of the Year" and "Licensing Deal of,the Year" ...
Cached Biology Technology:Gold solution for enhancing nanocrystal electrical conductance 2Gold solution for enhancing nanocrystal electrical conductance 3ThromboGenics is Shortlisted for "Biotech Company of the Year" and "Licensing Deal of the Year" at Scrip Awards 2009 2ThromboGenics is Shortlisted for "Biotech Company of the Year" and "Licensing Deal of the Year" at Scrip Awards 2009 3
(Date:12/19/2014)... , Dec. 18, 2014  23andMe, Inc., the leading ... study that pinpoints fine-scale differences in genetic ancestry of ... . Since immigrants first arrived more than ... has served as a meeting place for ... history and the ongoing mixing of peoples with African, ...
(Date:12/17/2014)... FORT BELVOIR, Va. , Dec. 15, 2014 ... its efforts to make it easier to detect ... supply chain. Today the agency started ... marking. The capability will validate the authenticity of ... supply chain. The new quality control measures will ...
(Date:12/17/2014)... 2014 Research and Markets ( ... "Global Chemical Sensor Market 2015-2019" report ... http://photos.prnewswire.com/prnh/20130307/600769 One major trend upcoming ... medical sensors in biomedical applications. Chemical sensors help ... correct diagnosis during surgical procedures. The Global Chemical ...
Breaking Biology News(10 mins):23andMe Study Sketches Genetic Portrait of the United States 223andMe Study Sketches Genetic Portrait of the United States 323andMe Study Sketches Genetic Portrait of the United States 4Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain 2Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain 3Global Chemical Sensor Market 2015-2019: Key Vendors are Abbott Laboratories, Bayer, Hoffmann La-Roche, Johnson & Johnson, NGK Spark Plugs and Robert Bosch 2
... remember the muscle shirts we wore in our teens and 20s? ... usually is obsolete. Yes, at the big 4-0 we begin to ... it may be gone. It,s an inevitable process of aging called ... A study conducted in mice with accelerated muscle loss at The ...
... 12, 2010) The wait is over for 16-year-old Francesco ... donor heart in a nine-hour transplant operation at Texas Children,s ... first child ever discharged from a pediatric hospital with an ... then, pediatric patients with VADs remained in the hospital, often ...
... have streamlined the process for synthesizing a family of compounds ... and have found that they represent a unique category of ... of the Journal of the American Chemical Society . ... as the kinamycins, which are naturally produced by bacteria during ...
Cached Biology News:Muscle loss finding may one day save physiques 2Texas Children's discharges history-making patient 2Scientists synthesize unique family of anti-cancer compounds 2
... Rack inserts fit into the ... allow you to greatly increase ... deepwell format plates at an ... from the shaker at once ...
For quantitative determination of Aldolase in Serum (an indicator of muscle damage). Ready-to-use liquid stable reagent. Formulated to eliminate interference from pyruvates. Application sheets are ...
Request Info...
... ,5-Bromo-4-chloro-3-indoxyl-beta-D-galactopyranoside C 14 H 15 ... ,M.W.= 408.63 ,Assay: Greater than ... DMF) ,Biological Activity: Blue color with ... Agrees with theoretical values ,Thin Layer ...
Biology Products: